Article Text

other Versions

Randomised controlled trial
Adding subcutaneous liraglutide to metformin reduces HbA1c more than adding oral sitagliptin in patients whose type 2 diabetes is poorly controlled with metformin alone
  1. Vivian Fonseca1,
  2. Cyrus Desouza2,
  3. Amna N Khan1
  1. 1Tulane University Health Sciences Center, New Orleans, Louisiana, USA
  2. 2Omaha VA Medical Center, Omaha, Nebraska, USA
  1. Correspondence to Vivian Fonseca
    Tulane University Health Sciences Center, 1430 Tulane Ave, SL-53, New Orleans, LA 70112, USA; vfonseca{at}

Statistics from

Commentary on:


Incretin hormones have recently been recognised in playing an important role in the pathogenesis and treatment of type 2 diabetes.1 Of these, glucagon-like peptide (GLP-1) is probably the most important but has a limitation due to its rapid breakdown by the enzyme dipeptidyl peptidase 4 (DPP-4) giving it a half life in circulation of approximately 2 min.

To overcome this limitation, two pharmacological approaches have been developed: (1) DPP-4 inhibitors (sitagliptin, saxagliptin) that increase the endogenous concentrations of GLP-1 through inhibition of DPP-4 and (2) GLP-1 mimetics (exenantide) or analogues (liraglutide). The former have the advantage of being taken orally whereas the latter are injectable. Previous studies have all focused on comparing incretin-based treatments to other medications such as sulphonylureas, metformin, thiazolidinediones or insulin.2 3 There are very few studies comparing one form of incretin therapy to …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.